Clinuvel Pharmaceuticals Limited Stock Deutsche Boerse AG
Stocks
UR9
AU000000CUV3
Pharmaceuticals
OTC Markets Traded|
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
| 6.369 EUR | +9.81% |
|
+14.50% | -14.29% |
| 06-15 | Clinuvel Pharmaceuticals Advances US Listing Plan With SEC Filing for Nasdaq ADS Upgrade | MT |
| 04-27 | Clinuvel Pharmaceuticals plans level II ADR upgrade and Nasdaq listing as CUVL | RE |
| Market Cap | 519M 364M 318M 294M 275M 516M 34.36B 3.49B 1.35B 16.91B 1.37B 1.34B 58.73B | P/E 2026 * |
13.9x | P/E 2027 * | 13.1x |
|---|---|---|---|---|---|
| Enterprise Value | 266M 186M 162M 150M 141M 264M 17.58B 1.78B 692M 8.65B 699M 684M 30.04B | EV / Sales 2026 * |
2.67x | EV / Sales 2027 * | 2.22x |
| Free-Float |
83.79% | Yield 2026 * |
0.62% | Yield 2027 * | 0.81% |
Last Transcript: Clinuvel Pharmaceuticals Limited
| 1 day | +9.81% | ||
| 1 week | +14.50% | ||
| Current month | +13.21% | ||
| 1 month | +9.09% | ||
| 3 months | +4.90% | ||
| 6 months | -17.81% | ||
| Current year | -14.29% |
| 1 week | 5.4 |  | 6 |
| 1 month | 5.1 | | 6 |
| Current year | 5.1 | | 7.39 |
| 1 year | 5.1 | | 7.68 |
| 3 years | 4.8 | | 12.68 |
| 5 years | 4.8 | | 27 |
| 10 years | 2.61 | | 27 |
| Manager | Title | Age | Since |
|---|---|---|---|
Philippe Wolgen
CEO | Chief Executive Officer | 63 | 2005-10-31 |
Peter Vaughan
DFI | Director of Finance/CFO | 42 | 2024-06-29 |
| Chief Tech/Sci/R&D Officer | - | - |
| Director | Title | Age | Since |
|---|---|---|---|
Karen Agersborg
BRD | Director/Board Member | - | 2018-01-28 |
Susan Smith
BRD | Director/Board Member | - | 2019-09-22 |
| Chairman | - | 2023-12-31 |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | +9.81% | +14.50% | - | - | 352M | |
| +0.33% | -0.25% | +18.76% | -22.11% | 62.05B | |
| +0.20% | -9.17% | +58.39% | +196.56% | 54.45B | |
| -3.92% | +37.40% | +37.40% | +37.40% | 43.09B | |
| +7.62% | +8.48% | -51.93% | -58.14% | 36.37B | |
| +0.79% | -1.69% | +55.35% | -33.92% | 29.02B | |
| +0.56% | +28.85% | +151.81% | -50.31% | 25.38B | |
| -0.10% | -8.91% | +43.87% | +55.34% | 19.62B | |
| +1.74% | +4.39% | -3.12% | +107.49% | 16.89B | |
| -0.05% | +0.41% | +56.32% | +94.95% | 15.93B | |
| Average | +1.74% | +2.39% | +40.76% | +36.36% | 33.64B | |
| Weighted average by Cap. | +0.71% | +1.18% | +37.09% | +36.26% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 99.46M 69.73M 60.8M 56.31M 52.71M 98.86M 6.58B 668M 259M 3.24B 262M 256M 11.25B | 105M 73.87M 64.41M 59.65M 55.84M 105M 6.97B 708M 274M 3.43B 277M 271M 11.91B |
| Net income | 35.97M 25.22M 21.99M 20.36M 19.06M 35.75M 2.38B 242M 93.62M 1.17B 94.66M 92.63M 4.07B | 38.2M 26.78M 23.35M 21.63M 20.25M 37.97M 2.53B 257M 99.44M 1.24B 101M 98.38M 4.32B |
| Net Debt | -254M -178M -155M -144M -134M -252M -16.78B -1.7B -660M -8.26B -668M -653M -28.69B | -286M -201M -175M -162M -152M -284M -18.92B -1.92B -745M -9.31B -753M -737M -32.34B |
| Date | Price | Change | Volume |
|---|---|---|---|
| 26-06-19 | 6.000 € | +3.45% | 0 |
| 26-06-18 | 5.800 € | -0.03% | 0 |
| 26-06-17 | 5.802 € | +7.44% | 562 |
| 26-06-16 | 5.400 € | -1.85% | 35 |
| 26-06-15 | 5.502 € | +5.00% | 0 |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Quarterly revenue - Rate of surprise
- Stock Market
- Stocks
- CUV Stock
- UR9 Stock
Select your edition
All financial news and data tailored to specific country editions
